Michael Weiser is listed as an executive officer and director on 10 SEC Form D filings by 3 issuers between Sep 2009 and Jul 2016: ZIOPHARM ONCOLOGY INC (Boston, MA — biotechnology — 2009–2016; $120M reported sold to 26 investors), EMISPHERE TECHNOLOGIES INC (Roseland, NJ — pharmaceuticals — 2010–2013; $35.2M reported sold to 16 investors) and Foresight Biotherapeutics, Inc. (New York, NY — biotechnology — 2011–2013; $15M reported sold to 2 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as executive officer and director, over about 7 years. Across those companies the filings report $170.2M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 1 court case matching the name, 1 bankruptcy case matching the name listed in Key records below.
What this means 2 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 10 public filings for Michael Weiser and found 6 differences: Industry group changed between filings; Reported revenue range changed between filings; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
